After 7 then 13 valent pneumococcal conjugate vaccine (PCV) implementation in France in children, we will evaluate the impact of this vaccination on invasive pneumococcal disease (IPD). We will describe the clinical characteristics of IPD, pneumococcus serotyping, underlying conditions and vaccination status.
Isolate of Streptococcus pneumoniae from at least one blood culture, or pleural fluid, or joint fluid, or cerebrospinal fluid or other normally sterile body site, or if there is a positive blood polymerase chain reaction (PCR).
Pneumococcal strain not transmetted to National Reference Center for Pneumococci or to Regional Pneumococci Observatory
Children with invasive pneumococcal disease for whom the pneumococcal strain is sent to the National reference Center for Pneumococci for serotyping
Case-only
Prospective
Not listed
Severity of invasive pneumococcal disease
Number of severe cases according to age and pneumococcal serotypes distribution
Impact of vaccines
Number of invasive pneumococcal disease according to vaccine serotypes
Click on the lead sponsor to view all of their trials.
Association Clinique Thérapeutique Infantile du val de Marne
Lead sponsor
Pfizer
Collaborator
